PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Sacituzumab Tirumotecan

Drugs in development · updated 30 October 2026

Sacituzumab Tirumotecan: clinical trials and development status

Other names and codes: SKB264

FDA substance registryNot approved in the USNo EMA authorisationEstimated launch Dec 2027 – Oct 2028 (Phuturdex estimate)

As of 30 October 2026 Sacituzumab Tirumotecan is in 113 active clinical trials (recruiting or ongoing, phases I–III) for 33 diseases. The most advanced phase is III.

113Active trials
IIIMost advanced phase
33Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Sacituzumab Tirumotecan and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov. Showing 30 of 33 diseases.

DiseaseMost advanced phaseActive trialsReference trial
Non-small-cell lung carcinomaIII23NCT06305754
Triple-negative breast neoplasmIII10NCT06279364
Breast neoplasmIII8NCT06966700
Lung neoplasmIII5NCT06312137
Uterine cervix neoplasmIII5NCT07216703
Endometrial neoplasmIII3NCT06952504
Ovarian neoplasmIII3NCT06824467
Bladder neoplasmIII2NCT07419295
CarcinomaIII1NCT06312137
Esophagus adenocarcinomaIII1NCT06356311
Fallopian tube neoplasmIII1NCT06824467
Esophageal squamous cell carcinomaII6NCT07823270
Biliary tract neoplasmII4NCT07850791
MetastasisII4NCT07511023
Brain NeoplasmsII3NCT07458113
Esophageal neoplasmI–II3NCT06469944
Head and neck squamous cell carcinomaII3NCT07778368
Lung small cell carcinomaII3NCT07501169
Transitional cell carcinomaII3NCT07662863
AdenocarcinomaII2NCT07689292
NeoplasmII2NCT07785609
Ovarian epithelial carcinomaII2NCT07341100
Prostatic NeoplasmsII2NCT07639086
ThymomaII2NCT07324629
Adenoid cystic carcinomaII1NCT07521670
CholangiocarcinomaII1NCT07105852
Clear cell adenocarcinomaII1NCT07718854
Colorectal neoplasmI–II1NCT06428409
Non-muscle invasive bladder neoplasmI–II1NCT06637423
Papillary thyroid cancerII1NCT07521670

Everything on Sacituzumab Tirumotecan

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch